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Accommodation refers to a condition in which a transplant (or any tissue) appears to 
resist immune-mediated injury and loss of function.  Accommodation was discovered and 
has been explored most thoroughly in ABO-incompatible kidney transplantation.  In this 
setting, kidney transplants bearing blood group A or B antigens often are found to 
function normal in recipients who lack and hence produce antibodies directed against the 
corresponding antigens.  Whether accommodation is owed to changes in anti-blood group 
antibodies, changes in antigen or a change in the response of the transplant to antibody 
binding are critically reviewed and a new working model that allows for the kinetics of 
development of accommodation is put forth.  Regardless of how accommodation 
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develops, observations on accommodation in ABO-incompatible transplantation offer 
lessons applicable more broadly in transplantation and in other fields. 
 
Those who first engaged in the practice of clinical organ transplantation believed that 
kidney donors and recipients should be compatible for ABO blood groups (1-4), that is 
kidneys from blood group A and/or B donors should not be transplanted into recipients 
lacking the corresponding antigens.  Soon, however, anecdotal experience suggested that 
ABO-incompatible kidney transplants could be safely performed (5-7), until shortly 
thereafter experience suggested otherwise (8-10).  Thus, ~35% of ABO-incompatible 
kidney transplants never functioned compared with 5% of ABO-compatible transplants.  
The immediate failure of ABO-incompatible transplants could be caused by ischemia-
reperfusion injury or anti-blood group antibodies or anti-HLA antibodies, any 
combination of which could generate what later would be called hyperacute rejection 
(Figure 1).  Of the ABO-incompatible transplants that did evidence function, at least one 
half lost function within three months (versus <25% of ABO-compatible transplants).  
These transplants probably suffered early acute, antibody-mediated or accelerated cellular 
rejection of both.  Figure 2 shows the course of an ABO-incompatible transplant that was 
probably destroyed by early acute rejection.  Approximately 25% of ABO-incompatible 
transplants continued to function however and those functioning at 3 months survived 
thereafter as well as did ABO-compatible transplants (10).1
 
  The decades since these 
early reports have brought significant improvement in the preparation (e.g. antibody 
depletion, screening for anti-HLA), care and overall outcome of ABO-incompatible 
kidney transplants; however, results of some surveys still reveal for early acute rejection 
followed by a course approaching that of ABO-compatible transplants thereafter (11-13).  
Why are some ABO-incompatible kidney transplants subject to devastating and lethal 
injury during the early weeks after transplantation and what allows ABO-incompatible 
transplants to avoid ongoing susceptibility to antibody-mediated injury?  Below we offer 
our perspectives on these questions. 
An immunologist's view of ABO-incompatible transplantation 
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As an extension of classic principles of immunology, the outcome of ABO-incompatible 
transplants should be uniformly poor.  The key variables for interaction of anti-blood 
group antibodies with cells bearing the corresponding blood group substances have been 
known over 90 years.  Figure 3 illustrates experiments showing that the concentration of 
anti-blood group antibodies and the concentration of human complement determine the 
extent of lysis of human erythrocytes exposed to these factors in vitro.  If labeled 
erythrocytes with anti-blood group antibodies bound to the corresponding antigens are 
introduced into the circulation, the erythrocytes are rapidly and reliably cleared (Figure 
3).  Even those with the lowest concentrations of IgM in blood specific for foreign blood 
group antigens activate complement to a sufficient extent to induce complement-
mediated clearance of the erythrocytes (14, 15).  If the fate of ABO-incompatible 
transplants was faithfully modeled by experiments testing interaction of antibodies and 
complement with ABO-incompatible erythrocytes then one might expect that ABO-
incompatible kidney transplants in recipients with appreciable levels of anti-blood group 
antibodies would exhibit notable complement-mediated changes, if not "lysis."  
 
The targets of anti-blood group antibodies in ABO-incompatible transplants are 
endothelial cells and endothelial cells are not faithfully modeled by erythrocytes.  One 
limitation of erythrocytes is the small surface area, particularly as investigated in vivo.  
The considerably greater surface area of endothelium of a transplant might absorb much 
or all anti-blood group antibody from blood but, as a result, deposit a lower density of the 
antibody on surface of each endothelial cell.  However, under optimal conditions, a single 
molecule of IgM bound to the surface of an erythrocyte can initiate activation of 
complement to a sufficient extent to lyse the erythrocyte (16) and in ABO-
incompatibility, the impact of IgM predominates.  In this system, 800 IgG molecules 
must be bound to generate lysis (17).  In an homologous in vivo system, attachment of 
one molecule of IgM to an erythrocyte could still effect complement-dependent clearance 
while at least 2000 molecules of IgG had to attach to initiate complement activation (18).  
Thus, the greater surface area of endothelium in a kidney cannot by itself explain why 
ABO-incompatible kidney transplants are not severely injured or rapidly destroyed 
immediately upon reperfusion by the recipient.  
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Another explanation for absence of lysis in ABO-incompatible kidney transplants is 
intrinsic resistance of the transplant and cellular elements of the transplant to 
complement-mediated injury.  Endothelial cells and indeed all nucleated cells are not 
inert targets for attack by antibodies and complement.  Rather, endothelial cells resist 
complement-mediated injury through various properties of cell membrane and cell 
metabolism that are less available or unavailable in erythrocytes.  The surface of 
endothelial cells is decorated by acidic saccharides, such as heparan sulfate, and by 
complement regulatory proteins that slow and potentially block activation of complement 
(19).  Further, nucleated cells actively dispose of the products of complement activation, 
profoundly modifying the kinetics of injury and introducing the potential for repair (20-
23).  Perhaps it is not surprising then that the pathology of hyperacute rejection is not 
characterized by "lysis" of cells but rather by ultra-structural changes in plasma 
membranes (and by "regional" changes such as aggregation of platelets and variable 
attachment of neutrophils) that reflect fewer membrane attack complexes than are needed 
for lysis of endothelial cells (24-27).  Thus, activation of complement in an organ 
transplant sparks a race between the generation and disposal of terminal complexes and 
the development of hyperacute rejection requires either the rapid and quantitative 
generation of membrane attack complexes on endothelial cells or the compromise of 
endothelial cell defenses.  The lower density of IgM bounding in newly reperfused ABO-
incompatible transplants usually cannot overcome endothelial defenses (xenogeneic 
organ grafts in contrast have intrinsically defective control of heterologous complement 
and hence the same levels of anti-endothelial antibodies reliably induce hyperacute 
rejection (28).  Consistent with this concept, most ABO-incompatible transplants 
performed before methods for antibody depletion were used did not undergo hyperacute 
rejection (10, 29).  
 
Most ABO-incompatible transplants performed in the era before antibody removal was 
performed underwent early acute rejection.  Early acute rejection (antibody-mediated 
and/or accelerated cellular rejection) requires far less complement activation (~10% of 
level required for hyperacute rejection) (30-34).  The activation of smaller amounts of 
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complement on endothelial cells triggers endothelial cell "activation," characterized by 
changes in blood vessel physiology from hindering to promoting coagulation, 
inflammation and vasoconstriction (31, 33).   
 
Classical studies on the fate of erythrocytes with bound antibodies might not faithfully 
represent organ transplants but they do provide a further explanation for the scarcity of 
hyperacute rejection of ABO-incompatible transplants compared to the frequency that 
would be expected in recipients with IgG antibodies against donor HLA.  After human 
erythrocytes are exposed to IgM anti-blood group antibodies in vitro and infused in 
human subjects, the erythrocytes are rapidly cleared (Figure 4) and potentially destroyed 
(14).  However, while practically all erythrocytes are removed from the circulation, under 
some condition erythrocytes with bound anti-blood group antibody are not destroyed and 
indeed reenter the circulation, surviving as long as control erythrocytes (to which 
antibody was not bound) (35).  In this setting, activation of complement by IgM actually 
protects the erythrocytes by generating C3d that blocks further covalent attachment of C3 
or C4 to the surface.  Blocking of reactive sites on endothelium with C3d or C4d might 
limit the number of membrane attack complexes present at a given time and contribute 
the low frequency of hyperacute rejection in ABO-incompatible transplantation.  
However, this mechanism should not prevent development of acute rejection because far 
less activation of complement is needed to generate that condition.    
 
Given these considerations, why does hyperacute rejection of ABO-incompatible 
transplants sometimes occur?  Comparison of outcomes of donated left versus right 
kidneys indicate that kidney donors vary considerably in susceptibility of their kidneys to 
acute injury (36-38).  The nature of this variation is poorly understood but much of the 
variation is manifest early after transplantation, especially in susceptibility to ischemia-
reperfusion injury. Occasionally, preservation or ischemia-reperfusion injury or 
concurrent donor-specific anti-HLA antibodies in combination with anti-donor blood 
group antibodies could increase the activation of complement to an extent to cause 
hyperacute rejection.  Such a concept is consistent with descriptions of the clinical course 
and pathology of transplants performed in the era before antibody depletion was 
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performed.  For instance, in one series of 12 subjects, none of four transplants of kidneys 
from living ABO-incompatible donors exhibited immediate failure and pathology 
consistent with hyperacute rejection whereas 3 of 8 ABO-incompatible transplants from 
deceased donors in recipients not depleted of antibodies exhibited immediate non-
function and inflammation consistent with hyperacute rejection (29).   
 
Since ABO-incompatible transplants are susceptible to early antibody-mediated rejection 
it is not surprising that the level of anti-donor blood group antibodies in the recipient at 
the time of kidney transplantation or before the antibodies are depleted predicts the early 
outcome of transplants (11, 12, 39-43).  Consistent with the concepts regarding 
differential susceptibility to hyperacute and acute antibody-mediated rejection are 
observations on the transplantation of kidneys from donors of blood group A2.  Blood 
group A2 binds less anti-blood group antibody than blood group A1 and kidneys of blood 
group A2 rarely undergo hyperacute rejection (39, 44-46); but do sometimes exhibit early 
acute antibody-mediated rejection and graft loss (11, 47, 48).  
 
Defiance of immunology in ABO-incompatible transplantation 
In striking contrast to the linear relationship between concentration of antibodies against 
foreign blood groups and lysis of target cells in vitro and there can be practically no 
relationship between the levels of antibodies against donor blood groups in the blood of 
the recipient and the function of an ABO-incompatible kidney transplant (Figure 5), 
especially after the period of risk of early acute injury has passed.  Once an ABO-
incompatible transplant is successfully perfused by the blood of the recipient and function 
is established for some period, the antibodies implicated in the immediate demise of 
ABO-incompatible transplants can return to the circulation without harming the 
transplant.  Abrupt increases in the levels of anti-donor blood group antibodies are 
sometimes observed coincident with rejection, for reasons we later discuss, but, high 
levels do not foreclose the fate of a graft.  One of us first observed this paradox in the 
1980s (49).  An individual of blood group O received a kidney from a donor of blood 
group A.  The recipient was depleted of antibodies by plasma exchange before and 
immediately after transplantation.  Over days however antibodies specific for donor 
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blood group returned to the circulation and neither the presence nor the level in the blood 
correlated with the function of the incompatible graft (Figure 5).  Others observed a 
similar phenomenon (50-53), but no explanation had been offered.   
 
Changes in antibody in ABO-incompatible transplantation 
Thinking as immunologists, we (and others) believed the most likely explanation for the 
happy coexistence of the transplant with antibodies directed against donor antigens was 
that either the antibodies or the antigen had changed in ways that precluded the antibody-
antigen interactions observed in vitro or upon reperfusion of the transplant.  At the time 
of transplantation antibodies specific for blood groups of the donor are clearly capable of 
recognizing and binding to antigens expressed in the graft since the levels of donor-
specific anti-blood group antibodies decrease drastically after reperfusion of transplants.  
Figure 2 illustrates this phenomenon in one of the first reports of deliberate ABO-
incompatible transplantation in a recipient from whom antibody was not depleted (we do 
not illustrate our recipient because plasmapheresis was performed immediately after 
transplantation).  During the days that follow, anti-blood group antibodies often return to 
the circulation of recipients regardless of whether antibodies had been depleted at the 
time of transplantation.  The levels in some recipients are below or at the baseline levels 
before transplantation and the levels in some others "rebound" to exceed the baseline (42, 
50, 52-54).  In some series, the rebound to higher levels is associated with early antibody-
mediated rejection.  Investigation of levels of antibodies against donor blood groups and 
B cell responses has suggested that decreased production of donor-specific anti-blood 
group antibodies can be detected in graft recipients and the suggestion has been made that 
perhaps this decrease explains the well-being of ABO-incompatible kidney transplants 
(55, 56).  However, the general experience has been that at least some recipients of ABO-
incompatible kidney transplants produce substantial amounts of antibody against the 
donor antigen and the preponderance of ABO-incompatible transplants contain deposits 
of C4d, in the absence of impaired function and consistent with ongoing binding of anti-
donor antibodies (57-59).  Even more to the point, the extent of antibody rebound after 
the first weeks appears to have little or no impact on the long-term outcome (Figure 5) 
(60, 61).   
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One problem that confounds investigation of the levels of antibodies against donor-blood 
groups in ABO-incompatible transplantation is that at a given point in time the transplant 
can absorb a substantial amount of antibody against donor blood group antigens (Figure 
2).  In experimental models, donor-specific antibodies have been quantitatively depleted 
by perfusion of kidneys expressing antigens of interest (25, 62, 63).  The absorption of 
substantial amounts donor-specific antibodies, whether those directed against xenogeneic 
antigens or blood groups or HLA antigens leaves in the circulation antibodies that have 
lower avidity interactions with donor antigens or antibodies directed antigens of lower 
abundance in the graft and conceivably no appreciable antibodies of pathogenic 
significance.  We shall discuss this problem below. 
 
Changes in antigen in ABO-incompatible transplants 
Could the antigen in the graft change in ways that hinder antibody binding?  Based on 
binding of lectins and monoclonal antibodies specific for human blood groups we 
concluded that antigens in the graft did not change (49, 64).  Using labeled blood group 
antigens as probes, we also found that at least some antibodies deposited in the kidney 
transplants were specific for blood group of the donor (64) (previously, anti-blood group 
antibodies had been eluted from an ABO-incompatible kidney transplant that was 
undergoing rejection) (65).  On the other hand, the group in Göteborg, which had been 
conducting numerous ABO-incompatible transplants, also conducted elegant biochemical 
and immunochemical analysis of neutral glycolipid extracts from transplants (45, 47, 53).  
This work suggested that kidneys from donors of blood group A2, which could be safely 
transplanted into recipients with anti-A antibodies, contained A2 antigen that was less 
reactive with anti-A2 antibodies (45).  More pertinent perhaps, was the observation that 
blood group substances could change qualitatively and quantitatively after transplantation 
and perhaps these changes could explain the better than expected outcomes (47, 66).  We 
know of no work since then that would dispute the possibility that blood group antigen in 
transplants changes or decreases over time and that less antibody binds to graft as a 
result.  Nevertheless, our subsequent work would tend to limit the impact of changes in 
antigen.  First, using a foot printing approach to identify carbohydrate epitopes actually 
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bound by antibodies in a related system (antibody binding to Galα1-3Gal on swine cells) 
we found that even under the most optimal conditions only a small fraction of epitopes 
are likely occupied by antibody (67, 68).  Second, we found that steric hindrance in part 
limited antibody binding.  And, third, and probably most important we found that while 
antibody binding was likely the limiting event in immediate (hyperacute) rejection, the 
pathogenesis of which depends on rapid assembly of complement membrane attack 
complexes, antibody binding does not limit the molecular events the generate acute 
vascular (antibody-mediated) rejection caused by activation of endothelial cells in the 
graft (30, 31, 69).  Antibody and complement induced activation of endothelial cells 
requires less than 10% as much antibody binding as the changes in endothelium believed 
to underlie hyperacute rejection and make the avoidance of rejection by loss of antigen a 
rather daunting challenge (70).  Thus, neither changes in the antibodies directed against 
donor blood groups nor in the blood groups expressed in kidney transplants persuasively 
explained the success of ABO-incompatible transplantation. 
 
Acquired resistance to injury by antibody and complement 
When fundamental principles of immunology failed to explain the success of ABO-
incompatible transplantation, we turned to a new biological paradigm - that success might 
reflect the accommodation of the graft to a hostile environment.  The observations in 
ABO-incompatible transplantation in patients appeared to be recapitulated in 
experimental efforts to prolong the survival of porcine organs transplanted into non-
human primates.  The xenotransplantation model had the advantage that rejection always 
occurred if the recipient was not depleted of xenoreactive antibodies but when those 
antibodies were removed a graft might function for a period of days after antibodies 
returned to the circulation of the recipient (63, 71).  The model allowed us to study the 
antibodies in serum and the antibodies deposited in functioning grafts (28, 63).  This 
work confirmed the idea that a transplant could undergo changes unrelated to antigen 
expression that would enable the transplant to resist otherwise devastating immune-
mediated injury.  We named this change "accommodation" (28). 
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Accommodation has been observed frequently during the past 25 years.  If one applies 
the definition of accommodation we first used - continued function of an organ transplant 
despite the presence in the recipient of antibodies against donor antigens expressed in the 
graft - accommodation is likely to be found in most ABO-incompatible transplants and is 
likely the most common outcome of such transplants, at least for a time.  Accommodation 
also occurs, although less often, in ABO-compatible transplants when recipients are 
found to have antibodies specific for donor-HLA (72-74).  The most pressing questions 
are what generates and what maintains accommodation.   
 
Mechanism(s) of accommodation 
Although antibodies directed against blood group antigens of the donor clearly could 
initiate severe vascular rejection, what changes could make a graft inured to the presence 
of such antibodies in a recipient was unknown when ABO-incompatible transplantation 
was pursued in the 1980s.  Two possibilities considered at the outset were: (i) that 
transplantation inflicts injury that renders a kidney highly susceptible to antibody and 
complement but repair of this injury engenders resistance; and (ii) that sub-lethal injury 
would induce a condition of increased resistance to cytotoxicity (28).  We think both 
concepts are correct at least during the initial hours and days after transplantation, 
cytoprotective factors are essential to overcoming the ischemic injury inevitably suffered 
during transplantation.  Furthermore, the cytoprotective factors, such as HO-1 expression 
(75) and AKT activation (76) are inducible or activated under conditions of stress and in 
this way heighten the protective posture needed for the transplant to survive (Figure 1).  
However, if cytoprotection is essential for accommodation to occur, it is not the 
process(s) that sustains the function of transplants under persistent assault by antibodies 
and complement or other noxious factors.  Nor do heightened expression cytoprotective 
genes and proteins determine the ultimate outcome of transplants (54, 77, 78). 
  
Rather, we have explored and will soon report other processes and changes we think 
sustain the functional integrity of transplants in the face of ongoing attack by complement 
and noxious substances and hence represent accommodation manifest in ABO-
incompatible transplants, as listed in Figure 1.  This new model of accommodation 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
springs from clinical observations of ABO-incompatible transplants suggesting existence 
of a period of vulnerability followed by ongoing loss of vulnerability.  We believe this 
model might have broader application as discussed below.  This model, actually a 
working hypothesis, shown in Figure 1 accounts for molecular and physiologic changes 
that would prevent or reverse: (i) the immediate or hyperacute rejection; (ii) the "early" 
irreversible rejection observed within the first weeks after transplantation; but stresses 
(iii) processes that confer ongoing repair and a new higher threshold for injury lethal 
injury from complement and phagocyte activation.  The delayed onset of increased 
capacity for repair may reflect in part changes in the biosynthesis of antibody engendered 
by earlier interaction of antibodies and complement and phagocytes with antigen targets 
(79).  The increased threshold for injury may reflect in part remodeling of blood vessels 
and supporting structures (80).  
 
Some lessons from accommodation of ABO-incompatible transplants 
The discovery and investigation of accommodation in ABO-incompatible transplantation 
has brought insights and lessons potentially applicable more broadly in transplantation 
and in other fields.  We shall discuss a few of these in closing. 
 
One lesson, mentioned above, concerns the possibility that antibodies, or absence thereof, 
in the blood of transplant recipient might misrepresent the state of immunity to the donor 
and the presence or absence of accommodation.  As shown above in Figure 2 and in 
many experimental settings, ABO-incompatible transplants can absorb much of the 
donor-specific antibody from the circulation of the recipient.  Therefore, the level of 
donor-specific antibodies in the blood does not necessarily reflect the level of antibody 
produced or the amount bound to the graft.  At an extreme, a recipient with no detectable 
donor-specific antibodies in blood might nonetheless produce antibodies that bind to and 
act on the graft.  To test the possibility, we examined donor-specific B cell responses in a 
series of (ABO-compatible) kidney transplant recipients that had no appreciable donor-
specific antibodies in their blood (81).  All of these subjects and nearly all others 
examined since exhibit a donor-specific B cell response characterized by secretion of 
donor specific IgM and sometimes donor-specific IgG during the first several months 
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after transplantation.  Absence of these antibodies in the blood probably reflects 
absorption to the transplant and accommodation to the bound antibody.  Consistent with 
this possibility is low titer of donor-specific blood group antibodies in many recipients of 
ABO-incompatible kidney transplants and the high frequency of C4d deposits observed 
in ABO-incompatible transplants with unimpaired function (57-60), the combination of 
which suggests accommodation.    
 
As another lesson, the studies on C4d in ABO-incompatible transplantation and the 
classical work on the fate of erythrocytes with bound anti-blood group IgM (35) should 
remind us that C4d is not pathogenic.  Every site with covalently bound C4d is 
unavailable for reaction with C3 and C4 and hence protected (82).  If C4d sometimes 
marks the presence underlying disease it also marks accommodation and mechanistically 
the inert property of C4d is more in keeping with accommodation.  
 
Another lesson emerging from investigation of ABO-incompatible transplantation and 
later from investigation of xenotransplantation concerns the how one might view the 
processes involved in rejection and accommodation in the broader context of host 
defense.  The responses of blood vessels to activation of complement (and/or interaction 
with activated phagocytes) characteristic of rejection reflect initial physiologic responses 
to foreign agents and noxious conditions (19, 80, 83).  At sites where an infectious agent 
or toxin is located, the responses contain microorganisms or toxins, preventing systemic 
spread (the problem in transplantation is that the assault and the response is diffuse in the 
grafted organ).  The processes we think reflect accommodation, then, are likewise 
orchestrated to reverse the pathophysiology introduced by the initial defenses once the 
organism or toxin is destroyed.  The "delay" of days or even weeks in the onset of 
accommodation is consistent with that concept.  Viewed in this way, accommodation is 
not merely the resistance to injury we first imagined and is better envisioned as a process 
that repairs injury and regenerate tissue functions.  Understood in this way, one can see 
how accommodation enables cancer cells to not only survive but also to expand and 
progress in hostile microenvironments and in the face of immune surveillance (84-86).  
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As one final "lesson" or hypothesis, we would suggest that if ABO-incompatible 
transplants are accommodated to ongoing production of anti-blood group antibodies, then 
one cause of rejection could be the loss or diminution of accommodation, as might occur 
with intercurrent illness or infection.  How would rejection owed to diminution of 
accommodation be manifest?  We think one manifestation would be loss of ability to 
absorb and metabolize donor-specific antibodies leading to the reappearance or to an 
increase in the level of donor-specific antibodies in blood.  If this concept is correct then 
graft injury or disease would precede rather than follow increases in the level of 
antibodies specific for donor blood groups.  Such an order of events - graft injury 
followed by increases in donor-specific antibodies - has been observed in the clinical 
setting for donor-specific anti-HLA antibodies (87, 88) and in the setting of experimental 
organ xenografts for anti-Gala1-3Gal antibodies (34, 89).  Conversely, restoration of 
accommodation would be marked by a decrease of anti-donor antibody levels in blood.  
From this perspective, donor-specific antibodies in blood could mark existing graft injury 
and represent a late and not an early indication of antibody-mediated injury.  Because 
ABO-incompatible transplantation crosses a barrier comprised by well-defined antigen 
and an antibody response to that antigen in all immune competent recipients, that setting 
should be ideal for testing hypotheses such as this one regarding accommodation.  
Although relatively infrequent, these transplants might thus shed light on avenues, 
besides immunosuppression, for treatment of autoimmunity and transplant rejection and 
new opportunities for targeting cancer and chronic infection. 
 
 
Footnotes: 
1. The outcomes were extrapolated from The Kidney Transplant Registry report of 1967 
(10) for living donor transplants; the results of deceased donor transplants were so poor, 
little sense could be distilled.  
 
References Cited 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
1. HUME DM, MERRILL JP, MILLER BF, THORN GW. Experiences with renal 
homotransplantation in the human: report of nine cases. Journal of Clinical Investigation. 
1955; 34: 327-382. 
2. MURRAY JE, HARRISON JH. Surgical management of fifty patients with 
kidney transplants including eighteen pairs of twins. Am J Surg. 1963; 105: 205-218. 
3. HAMBURGER J, CROSNIER J, DORMONT J. Experience with 45 Renal 
Homotransplantations in Man. Lancet. 1965; 1: 985-992. 
4. MOORE FD, BURCH GE, HARKEN DE, SWAN HJ, MURRAY JE, LILLIHEI 
CW. Cardiac and other organ transplantation. In the setting of transplant science as a 
national effort. JAMA. 1968; 206: 2489-2500. 
5. MURNAGHAN GF, JEREMY D, TRACY GD, FARNSWORTH RH, 
MCCREDIE KB. Successful human cadaveric renal homograft with major blood-group 
incompatibility. Lancet. 1967; 2: 852-854. 
6. STARZL TE, MARCHIORO TL, HERMANN G, BRITTAIN RS, WADDELL 
WR. Renal homografts in patients with major donor-recipient blood group 
incompatibilities. Surgical Forum. 1963; XIV: 214-216. 
7. STARZL TE, MARCHIORO TL, HOLMES JH, HERMANN G, BRITTAIN RS, 
STONINGTON OH, et al. Renal Homografts in Patients with Major Donor-Recipient 
Blood Group Incompatibilities. Surgery. 1964; 55: 195-200. 
8. STARZL TE, MARCHIORO TL, HOLMES JH, WADDELL WR. The incidence, 
cause, and significance of immediate and delayed oliguria or anuria after human renal 
transplantation. Surgery, Gynecology and Obstetrics. 1964; 118: 819-827. 
9. DUNEA G, NAKAMOTO S, STRAFFON RA, FIGUEROA JE, VERSACI AA, 
SHIBAGAKI M, et al. Renal Homotransplantation in 24 Patients. Br Med J. 1965; 1: 7-
13. 
10. GLEASON RE, MURRAY JE. Report from kidney transplant registry:  analysis 
of variables in the function of human kidney transplants. Transplantation. 1967; 5: 343-
359. 
11. RYDBERG L. ABO-incompatibility in solid organ transplantation. Transfus Med. 
2001; 11: 325-342. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
12. TOMA H, TANABE K, TOKUMOTO T. Long-term outcome of ABO-
incompatible renal transplantation. Urol Clin North Am. 2001; 28: 769-780. 
13. MONTGOMERY JR, BERGER JC, WARREN DS, JAMES NT, 
MONTGOMERY RA, SEGEV DL. Outcomes of ABO-incompatible kidney 
transplantation in the United States. Transplantation. 2012; 93: 603-609. 
14. CUTBUSH M, MOLLISON PL. Relation between characteristics of blood-group 
antibodies in vitro and associated patterns of redcell destruction in vivo. Br J Haematol. 
1958; 4: 115-137. 
15. MOLLISON PL, ENGELFRIET CP, CONTRERAS M. Blood transfusion in 
clinical medicine. London, England: Blackwell Scientific Publications, 1993. 
16. BORSOS T, RAPP HJ. Hemolysin titration based on fixation of the activated first 
component of complement: Evidence that one molecule of hemolysin suffices to sensitize 
an erythrocyte. Journal of Immunology. 1965; 95: 559-566. 
17. HUMPHREY JH. Haemolytic efficiency of rabbit IgG anti-Forssman antibody 
and its augmentation by anti-rabbit IgG. Nature. 1967; 216: 1295-1296. 
18. SCHREIBER AD, FRANK MM. Role of antibody and complement in the 
immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM 
complement-fixing sites and effects of their interaction with serum. J Clin Invest. 1972; 
51: 583-589. 
19. PLATT JL, WRENSHALL LE, JOHNSON GB, CASCALHO M. Heparan 
Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues. Adv Exp Med Biol. 
2015; 865: 123-140. 
20. KOSKI CL, RAMM LE, HAMMER CH, MAYER MM, SHIN ML. Cytolysis of 
nucleated cells by complement: cell death displays multi-hit characteristics. Proceedings 
of the National Academy of Science,USA. 1983; 80: 3816-3820. 
21. MORGAN BP, DANKERT JR, ESSER AF. Recovery of human neutrophils from 
complement attack: removal of the membrane attack complex by endocytosis and 
exocytosis. J Immunol. 1987; 138: 246-253. 
22. SHIN ML, CARNEY DF. Cytotoxic action and other metabolic consequences of 
terminal complement proteins. Progress in Allergy. 1988; 40: 44-81. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
23. MORGAN BP. Complement membrane attack on nucleated cells: resistance, 
recovery and non-lethal effects. Biochemical Journal. 1989; 264: 1-14. 
24. PLATT JL, VERCELLOTTI GM, LINDMAN BJ, OEGEMA TR, JR., BACH 
FH, DALMASSO AP. Release of heparan sulfate from endothelial cells. Implications for 
pathogenesis of hyperacute rejection. J Exp Med. 1990; 171: 1363-1368. 
25. PLATT JL, FISCHEL RJ, MATAS AJ, REIF SA, BOLMAN RM, BACH FH. 
Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. 
Transplantation. 1991; 52: 214-220. 
26. VERCELLOTTI GM, PLATT JL, BACH FH, DALMASSO AP. Enhanced 
neutrophil adhesion to xenogeneic endothelium via C3bi. Journal of Immunology. 1991; 
146: 730-734. 
27. SAADI S, PLATT JL. Transient perturbation of endothelial integrity induced by 
natural antibodies and complement. Journal of Experimental Medicine. 1995; 181: 21-31. 
28. PLATT JL, VERCELLOTTI GM, DALMASSO AP, MATAS AJ, BOLMAN 
RM, NAJARIAN JS, et al. Transplantation of discordant xenografts: a review of 
progress. Immunology Today. 1990; 11: 450-456. 
29. WILBRANDT R, TUNG KSK, DEODHAR SD, NAKAMOTO S, KOLFF WJ. 
ABO blood group incompatibility in human renal homotransplantation. American Journal 
of Clinical Pathology. 1969; 51: 15-23. 
30. CASCALHO M, PLATT JL. The immunological barrier to xenotransplantation. 
Immunity. 2001; 14: 437-446. 
31. SAADI S, TAKAHASHI T, HOLZKNECHT RA, PLATT JL. Pathways to acute 
humoral rejection. American Journal of Pathology. 2004; 164: 1073-1080. 
32. CASCALHO M, PLATT JL. Basic mechanisms of humoral rejection. Pediatric 
Transplantation. 2005; 9: 9-16. 
33. BRUNN GJ, SAADI S, PLATT JL. Differential regulation of endothelial cell 
activation by complement and interleukin 1alpha. Circulation Research. 2006; 98: 793-
800. 
34. PLATT JL, CASCALHO M. Donor specific antibodies after transplantation. 
Pediatric Transplantation. 2011; 15: 686-690. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
35. ATKINSON JP, FRANK MM. Studies on the in vivo effects of antibody. Journal 
of Clinical Investigation. 1974; 54: 339-348. 
36. COSIO FG, QIU W, HENRY ML, FALKENHAIN ME, ELKHAMMAS EA, 
DAVIES EA, et al. Factors related to the donor organ are major determinants of renal 
allograft function and survival. Transplantation. 1996; 62: 1571-1576. 
37. LOUVAR DW, LI N, SNYDER J, PENG Y, KASISKE BL, ISRANI AK. 
"Nature versus nurture" study of deceased-donor pairs in kidney transplantation. J Am 
Soc Nephrol. 2009; 20: 1351-1358. 
38. TRAYNOR C, O'KELLY P, DENTON M, MAGEE C, CONLON PJ. 
Concordance of outcomes of pairs of kidneys transplanted into different recipients. 
Transpl Int. 2012; 25: 918-924. 
39. RYDBERG L, BREIMER ME, BRYNGER H, SAMUELSSON BE. ABO-
incompatible kidney transplantation (A2 to O). Qualitative and semiquantitative studies 
of the humoral immune response against different blood group A antigens. 
Transplantation. 1990; 49: 954-960. 
40. NELSON PW, HELLING TS, SHIELD CF, BECK M, BRYAN CF. Current 
experience with renal transplantation across the ABO barrier. Am J Surg. 1992; 164: 541-
544; discussion 544-545. 
41. SHIMMURA H, TANABE K, ISHIKAWA N, TOKUMOTO T, TAKAHASHI 
K, TOMA H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney 
transplantation. Transplantation. 2000; 70: 1331-1335. 
42. GLOOR JM, LAGER DJ, MOORE SB, PINEDA AA, FIDLER ME, LARSON 
TS, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living 
donors. Transplantation. 2003; 75: 971-977. 
43. BRYAN CF, CHERIKH WS, SESOK-PIZZINI DA. A2 /A2 B to B Renal 
Transplantation: Past, Present, and Future Directions. Am J Transplant. 2016; 16: 11-20. 
44. BRYNGER H, RYDBERG L, SAMUELSSON BE, SANDBERG L. Experience 
with 14 renal transplants with kidneys from blood group A (subgroup A2
45. BREIMER ME, SAMUELSSON BE. The specific distribution of glycolipid-
based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor 
) to O recipients. 
Transplantation Proceedings. 1984; 16: 1175. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
status of single individuals. A possible molecular explanation for the successful 
transplantation of A2 kidneys into O recipients. Transplantation. 1986; 42: 88-91. 
46. NELSON PW, HELLING TS, PIERCE GE, ROSS G, SHIELD CF, BECK ML, 
et al. Successful transplantation of blood group A2 kidneys into non-A recipients. 
Transplantation. 1988; 45: 316-319. 
47. RYDBERG L, BREIMER ME, SAMUELSSON BE, BRYNGER H. Blood group 
ABO-incompatible (A2 to O) kidney transplantation in human subjects: a clinical, 
serologic, and biochemical approach. Transplant Proc. 1987; 19: 4528-4537. 
48. WELSH KI, VAN DAM M, KOFFMAN CG, BEWICK ME, RUDGE CJ, 
TAUBE DH, et al. Transplantation of blood group A2 kidneys into O or B recipients: the 
effect of pretransplant anti-A titers on graft survival. Transplant Proc. 1987; 19: 4565-
4567. 
49. CHOPEK MW, SIMMONS RL, PLATT JL. ABO-incompatible renal 
transplantation: initial immunopathologic evaluation. Transplantation Proceedings. 1987; 
19: 4553-4557. 
50. ALEXANDRE GP, DE BRUYERE M, SQUIFFLET JP, MORIAU M, 
LATINNE D, PIRSON Y. Human ABO-incompatible living donor renal homografts. 
Neth J Med. 1985; 28: 231-234. 
51. ALEXANDRE GPJ, SQUIFFLET JP, DE BRUYERE M, LATINNE D, REDING 
R, GIANELLO P, et al. Present experiences in a series of 26 ABO-incompatible living 
donor renal allografts. Transplantation Proceedings. 1987; 19: 4538-4542. 
52. BANNETT AD, MCALACK RF, RAJA R, BAQUERO A, MORRIS M. 
Experiences with known ABO-mismatched renal transplants. Transplantation 
Proceedings. 1987; 19: 4543-4546. 
53. BREIMER ME, BRYNGER H, LE PENDU J, ORIOL R, RYDBERG L, 
SAMUELSSON BE, et al. Blood group ABO-incompatible kidney transplantation 
biochemical and immunochemical studies of blood group A glycolipid antigens in human 
kidney and characterization of the antibody response (antigen specificity and antibody 
class) in O recipients receiving A2 grafts. Transplant Proc. 1987; 19: 226-230. 
54. PARK W, GRANDE JP, NINOVA D, NATH KA, PLATT JL, GLOOR JM, et al. 
Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
protection against antibody-mediated injury. American Journal of Transplantation. 2003; 
3: 952-960. 
55. FAN X, LANG H, BROWN J, GIANNITSOS V, ZHANG L, ZHOU X, et al. 
Induction of human blood group A-antigen expression on mouse cells using lentiviral 
gene transduction. Human Gene Therapy. 2010; 21: 877-890. 
56. TASAKI M, SAITO K, NAKAGAWA Y, IMAI N, ITO Y, AOKI T, et al. 
Acquired Downregulation of Donor-Specific Antibody Production After ABO-
Incompatible Kidney Transplantation. Am J Transplant. 2016. 
57. HAAS M, RAHMAN MH, RACUSEN LC, KRAUS ES, BAGNASCO SM, 
SEGEV DL, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible 
renal allografts: correlation with histologic findings. Am J Transplant. 2006; 6: 1829-
1840. 
58. DORJE C, MJOEN G, STROM EH, HOLDAAS H, JENSSEN T, OYEN O, et al. 
One-year protocol biopsies from ABO-incompatible renal allografts compared with a 
matched cohort of ABO-compatible allografts. Clin Transplant. 2015; 29: 268-276. 
59. ISHIHARA H, ISHIDA H, UNAGAMI K, HIRAI T, OKUMI M, OMOTO K, et 
al. Evaluation of Microvascular Inflammation in ABO-Incompatible Kidney 
Transplantation. Transplantation. 2017; 101: 1423-1432. 
60. SHIMMURA H, TANABE K, ISHIDA H, TOKUMOTO T, ISHIKAWA N, 
MIYAMOTO N, et al. Lack of correlation between results of ABO-incompatible living 
kidney transplantation and anti-ABO blood type antibody titers under our current 
immunosuppression. Transplantation. 2005; 80: 985-988. 
61. ISHIDA H, KONDO T, SHIMIZU T, NOZAKI T, TANABE K. Postoperative 
rebound of antiblood type antibodies and antibody-mediated rejection after ABO-
incompatible living-related kidney transplantation. Transpl Int. 2015; 28: 286-296. 
62. COOPER DKC, HUMAN PA, LEXER G, ROSE AG, REES J, KERAAN M, et 
al. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in 
the baboon. Journal of Heart Transplantation. 1988; 7: 238-246. 
63. PLATT JL, TURMAN MA, NOREEN HJ, FISCHEL RJ, BOLMAN RM, BACH 
FH. An ELISA assay for xenoreactive natural antibodies. Transplantation. 1990; 49: 
1000-1001. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
64. BANNETT AD, MCALACK RF, MORRIS M, CHOPEK M, PLATT JL. ABO 
incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO 
antigens after transplant. Transplantation Proceedings. 1989; 21: 783-785. 
65. PAUL LC, VAN ES LA, DE LA REVIERE GB, EERNISSE G, DE GRAEFF J. 
Blood group B antigen on renal endothelium as the target for rejection in an ABO-
incompatible recipient. Transplantation. 1978; 26: 268-271. 
66. RYDBERG L, SAMUELSSON BE. Presence of glycosyltransferase inhibitors in 
the sera of patients with long-term surviving ABO incompatible (A2 to O) kidney grafts. 
Transfus Med. 1991; 1: 177-182. 
67. PARKER W, HOLZKNECHT ZE, SONG A, BLOCHER BA, BUSTOS M, 
REISSNER KJ, et al. Fate of antigen in xenotransplantation: implications for acute 
vascular rejection and accommodation. American Journal of Pathology. 1998; 152: 829-
839. 
68. EVERETT ML, LIN SS, WORRELL SS, PLATT J, PARKER W. The footprint 
of antibody bound to pig cells: evidence of complex surface topology. Biochemical & 
Biophysical Research Communications. 2003; 301: 751-757. 
69. SAADI S, HOLZKNECHT RA, PATTE CP, STERN DM, PLATT JL. 
Complement-mediated regulation of tissue factor activity in endothelium. Journal of 
Experimental Medicine. 1995; 182: 1807-1814. 
70. PARKER W, LIN SS, PLATT JL. Antigen expression in xenotransplantation:  
how low must it go? Transplantation. 2001; 71: 313-319. 
71. FISCHEL RJ, BOLMAN RM, PLATT JL, NAJARIAN JS, BACH FH, MATAS 
AJ. Removal of IgM anti-endothelial antibodies results in prolonged cardiac xenograft 
survival. Transplantation Proceedings. 1990; 22: 1077-1078. 
72. LYNCH RJ, PLATT JL. Escaping from Rejection. Transplantation. 2009; 88: 
1233-1266. 
73. CASCALHO MI, CHEN BJ, KAIN M, PLATT JL. The paradoxical functions of 
B cells and antibodies in transplantation. Journal of immunology. 2013; 190: 875-879. 
74. DIJKE EI, PLATT JL, BLAIR P, CLATWORTHY MR, PATEL JK, KFOURY 
AG, et al. B cells in transplantation. J Heart Lung Transplant. 2016. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
75. BACH FH, FERRAN C, HECHENLEITNER P, MARK W, KOYAMADA N, 
MIYATAKE T, et al. Accommodation of vascularized xenografts: Expression of 
"protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nature 
Medicine. 1997; 3: 196-204. 
76. KOCH CA, KANAZAWA A, NISHITAI R, KNUDSEN BE, OGATA K, 
PLUMMER TB, et al. Intrinsic resistance of hepatocytes to complement-mediated injury. 
Journal of Immunology. 2005; 174: 7302-7309. 
77. COURTNEY AE, MCNAMEE PT, MIDDLETON D, HEGGARTY S, 
PATTERSON CC, MAXWELL AP. Association of functional heme oxygenase-1 gene 
promoter polymorphism with renal transplantation outcomes. Am J Transplant. 2007; 7: 
908-913. 
78. COURTNEY AE, MAXWELL AP. Heme oxygenase 1: does it have a role in 
renal cytoprotection? Am J Kidney Dis. 2008; 51: 678-690. 
79. PLATT JL, KAUFMAN CL, GARCIA DE MATTOS BARBOSA M, 
CASCALHO M. Accommodation and related conditions in vascularized composite 
allografts. Curr Opin Organ Transplant. 2017; 22: 470-476. 
80. SAADI S, WRENSHALL LE, PLATT JL. Regional manifestations and control of 
the immune system. FASEB Journal. 2002; 16: 849-856. 
81. LYNCH RJ, SILVA IA, CHEN BJ, PUNCH JD, CASCALHO M, PLATT JL. 
Cryptic B cell response to renal transplantation. Am J Transplant. 2013; 13: 1713-1723. 
82. PLATT JL. C4d and the fate of organ allografts. J Am Soc Nephrol. 2002; 13: 
2417-2419. 
83. IHRCKE NS, WRENSHALL LE, LINDMAN BJ, PLATT JL. Role of heparan 
sulfate in immune system-blood vessel interactions. Immunology Today. 1993; 14: 500-
505. 
84. KOCH CA, KHALPEY ZI, PLATT JL. Accommodation: preventing injury in 
transplantation and disease. Journal of Immunology. 2004; 172: 5143-5148. 
85. PLATT JL, ZHOU X, LEFFERTS AR, CASCALHO M. Cell Fusion in the War 
on Cancer: A Perspective on the Inception of Malignancy. Int J Mol Sci. 2016; 17. 
86. CASCALHO M, PLATT JL. Harnessing B cells in immunotherapy. 
Immunotherapy. 2016; 8: 237-239. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
87. CARPENTER CB, D'APICE AJ, ABBAS AK. The role of antibodies in the 
rejection and enhancement of organ allografts. Adv Immunol. 1976; 22: 1-65. 
88. COOPER JE, GRALLA J, CAGLE L, GOLDBERG R, CHAN L, WISEMAN 
AC. Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific 
Antibodies Are Due To Acute Rejection Episodes. Transplantation. 2011; 91: 1103-1109. 
89. COLLINS BH, COTTERELL AH, MCCURRY KR, ALVARADO CG, MAGEE 
JC, PARKER W, et al. Cardiac xenografts between primate species provide evidence for 
the importance of the a-galactosyl determinant in hyperacute rejection. Journal of 
Immunology. 1995; 154: 5500-5510. 
90. DAUBER LG, REED LJ. ABO antibodies. I. Methods for quantification of ABO 
hemolysins and soluble blood group substances A and B (interim report). Rep No 818. 
Rep US Army Med Res Lab. 1969: 1-21. 
 
 
Figure Legends 
 
Figure 1.  Chronology of rejection and accommodation of ABO-incompatible kidney 
transplants. A. Rejection of ABO-incompatible kidney transplants.  Ischemia-
reperfusion injury and antibodies directed against donor blood group and possibly against 
HLA antigens activate the complement system.  If complement activation from this 
combination of factors is robust and fast, hyperacute rejection may ensue within minutes 
to hours of the time reperfusion.  Today, hyperacute rejection is rare because of cross 
matching and depletion of anti-blood group antibodies.  However, lower levels of these 
antibodies can induce early acute vascular rejection.  After several weeks, however, the 
risk of rejection of an ABO-incompatible graft is no higher than that of an ABO-
compatible graft.  One explanation for the decrease in the risk of rejection may be 
"accommodation" of the graft to ongoing presence of anti-blood group antibodies in the 
recipient. B. Accommodation of ABO-incompatible kidney transplants.  ABO-
incompatible kidney transplants exhibit heightened risk of antibody-mediated rejection 
during the first several weeks up to approximately one month after transplantation.  This 
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risk reflects the ongoing production of antibodies specific for blood group antigens in the 
graft.  Susceptibility to early rejection (and ischemia-reperfusion injury) is mitigated by 
intrinsic resistance of nucleated cells and tissues to complement mediated injury and by 
the immediate response to complement activation on cell surfaces.  Over a period of 
weeks, grafts acquire a higher level of resistance to injury by antibodies and complement.  
This heightened resistance reflects in part the repair of damage already inflicted and in 
part changes at the cellular and tissue level that reduce susceptibility to injury.  The 
condition in which a tissue or organ resists otherwise lethal injury by complement or 
other factors is called "accommodation." 
 
Figure 2. Concentration of anti-blood group antibodies in the blood before and after 
kidney transplantation.  Originally published by Hume et al. (Annals of the NY 
Academy of Sciences 120: 578, 1964) with permission of the publisher (John Wiley & 
Sons).  The figure (modified for clarity) depicts the concentration of anti-blood group B 
antibodies (1/titer determined using 2-fold dilutions, i.e. the reciprocal log2
 
) in a patient 
of blood group A before and after transplantation of a kidney from a donor of blood 
group B (solid line).  Also shown are the concentrations of anti-blood group B antibodies 
in two controls, patients of blood group O who received kidney transplants from donors 
of blood group O (dashed lines).  The figure shows that immediately upon 
transplantation, antibodies against donor blood group B are depleted from the blood 
(arrow; from 1:1024 to ~1:25) and within 12 hours are undetectable.  The figure also 
shows that anti-donor blood group antibodies are detected again 5 days after 
transplantation, likely the time that function deteriorates from rejection.  On day 7, 
urinary output decreased, presumably from rejection.  In two controls (blood type O 
kidneys in blood type O recipients) the levels of anti-blood group B antibodies do not 
change notably after transplantation.  The figure shows that a functioning transplant 
depletes all or nearly all anti-blood group antibody from a recipient. 
Figure 3. Lysis of human erythrocytes by blood group-
-
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.  The illustrations are from the US Army Medical 
Research Laboratory Report #818  and are presented with permission.  A. Lysis of 
-blood group 
  Three dilutions of a reference serum, 
used as a source of anti-blood group A antibodies were used to determine the QH50, the 
dilution of a serum that lyses 50% of a standard red cell suspension (QH50) in the 
presence of excess complement.  The QH50 for the three dilutions (shown at the bottom) 
indicate that lysis is a direct and predictable function of the concentration of anti-A 
antibodies.  B. Assay of various sources of human complement for ability to lyse 
erythrocytes when combined with serial dilutions of serum from an individual of 
blood group O.  A standard volume (0.1 ml) of serum containing anti-A or anti-B 
antibodies is combined with various volumes of absorbed human serum lacking anti-A or 
-B antibodies (i.e. human complement) and added to a standard preparation of washed A- 
or B-type erythrocytes.  The figure shows that lysis is a function of the amount of human 
complement added. 
Figure 4. Intravascular hemolysis of blood group A- and blood group B-
incompatible erythrocytes in human subjects.  This figure depicts classic experiments 
performed to ascertain the mechanism of clearance of blood group A and blood group B 
erythrocytes administered to human subjects with the corresponding anti-blood group 
antibodies.  Depending on the isotype and concentration of anti-A or -B blood group 
antibodies and the antigen density and the number of cells administered, clearance might 
be generated by immediate complement-mediated lysis (intravascular hemolysis) or by 
sequestration by phagocytes in spleen, liver or blood.  In the examples shown, 
erythrocytes are labeled in vitro with 51Cr and then a small volume (<1 ml) is given 
intravenously. A. Intravascular hemolysis of 51Cr-labeled blood group A and blood 
group B erythrocytes within minutes after administration to subjects with anti-A 
and anti-B antibodies.  Hemolysis occurs even in subjects whose antibody titers are too 
low to generate hemolysis in vitro.  The table is from M. Cutbush and P.L. Mollison, Brit 
J Haemat 4: 115, 1965 with permission of the publisher (John Wiley & Sons).  B. 
Intravascular hemolysis 51Cr-labeled erythrocytes of blood group B administered to 
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a subject of blood group (open circles) and 51Cr-labeled blood group A2 
erythrocytes into a subject of blood group O (solid circles).  Erythrocytes of blood 
group A2 have less antigen but intravascular hemolysis still occurs to the same extent 
(>99%), if slightly less quickly.  From Mollison's Blood Transfusion in Clinical Medicine
 
 
eleventh ed., H. G. Klein and D.J. Anstee (2005), Chapter 10, Fig 10.3.  C. Laboratory 
findings after transfusion of 140 ml of blood group A2 erythrocytes into a patient of 
blood group O.  Although the density of blood group A2 antigen is low, sufficient 
antibody is bound to decrease the concentration 32-fold (1:512 to 1:16) and to cause 
activation of complement and intravascular hemolysis, indicated by the presence of 
hemoglobin in plasma and urine.  Some erythrocytes were cleared by phagocytosis 
indicated by the increase in bilirubin.  The table is from C.P. Duvall et al. Transfusion 14: 
382, 1974, with permission of the publisher, John Wiley & Sons.   
Figure 5. Relationship or lack thereof between the concentrations of IgM and IgG 
specific for blood group A in a kidney transplant and function of the transplant.  A 
patient of blood group O received a kidney transplant from a donor of blood group A and 
the levels of IgM and IgG in the recipient specific for blood group A and the serum 
creatinine (an inverse measure of renal function) were measured at various times after 
transplantation.  Repeated biopsies confirmed the continued expression of blood group A 
on donor endothelium (not shown).  The figure depicts these values at times other than 
those immediately following antibody depletion.  The results reveal absolutely no 
relationship between the levels of antibodies directed against donor blood groups and the 
function of the transplant in contrast to the impact of anti-blood group antibodies on 
erythrocytes depicted in Figures 2-4.   
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